Childhood–juvenile multiple sclerosis: clinical characteristics and treatment

References

• Compston A, Coles A. Multiple sclerosis. Lancet 359, 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121–127 (2001).
   PubMed Web of Science ®Google Scholar
• Trapp B, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295–302 (1999).
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vokusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126, 770–782 (2003).
   PubMed Web of Science ®Google Scholar
• Duquette P, Murray TJ, Pleines J et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J. Pediatrics 111, 359–363 (1987).
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Deplano V, Faroni J et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult. Scler.3, 43–46 (1997).
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Pozzilli C, Liguori M et al. Prospective study of multiple sclerosis with early onset. Mult. Scler. 8, 115–118 (2002).
   PubMed Web of Science ®Google Scholar
• Simone IL, Carrara D, Tortorella C et al. Course and prognosis in early onset MS. Comparison with adult-onset forms. Neurology 59, 1922–1928 (2002).
   PubMed Web of Science ®Google Scholar
• Boiko A, Vorobeychik G, Paty D et al. Early onset multiple sclerosis. A longitudinal study. Neurology 59, 1006–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Gusev E, Boiko A, Bikova O et al. The natural history of early onset multiple sclerosis: comparison of data from Moskow and Vancouver. Clin. Neurol. Neurosurg. 104, 203–207 (2002).
   PubMed Web of Science ®Google Scholar
• Ghezzi A. Clinical characteristics of multiple sclerosis with early onset. Neurol. Sci. 25, S366–S369 (2004).
   Google Scholar
• Mikaeloff Y, Suissa S, Vallee et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J. Pediatr. 144, 246–252 (2004).
   PubMed Web of Science ®Google Scholar
• Ruggieri M, Iannetti P, Polizzi A et al. Multiple sclerosis in children under 10 years of age. Neurol. Sci. 25, S326–S335 (2004).
   PubMed Web of Science ®Google Scholar
• •Complete review of clinical and laboratory characteristics of MS in subjects under 10 years of age.
   Google Scholar
• Pinhas-Hamiel O, Sarova-Pinhas I, Achiron A. Multiple sclerosis in childhood and adolescence. Clinical features and management. Paediatr. Drugs 3, 329–336 (2001).
   PubMedGoogle Scholar
• Ruggieri M, Polizzi A, Pavone L, Grimaldi ME. Multiple sclerosis in children under 6 years of age. Neurology 53, 478–484 (1999).
   PubMed Web of Science ®Google Scholar
• Hanefeld F, Bauer HJ, Christen H et al. Multiple sclerosis in childhood: report of 15 cases. Brain Dev. 13, 410–416 (1991).
   PubMed Web of Science ®Google Scholar
• Duquette P, Girard M. Hormonal factors in susceptibility to multiple sclerosis. Curr. Opin. Neurol. Neurosurg. 6, 195–201 (1993).
   PubMedGoogle Scholar
• Tardieu M, Mikaeloff Y. Multiple sclerosis in children. Int. Multiple Sclerosis J. 11, 36–42 (2004).
   Google Scholar
• Dale RC, de Sousa C, Chong WK, Cox TCS, Harding B, Neville BGR. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123, 2407–2422 (2000).
   PubMed Web of Science ®Google Scholar
• Brass SD, Caramanos Z, Santos C et al. Multiple Sclerosis vs. acute disseminated encephalomyelitis in childhood. Pediatr. Neurol. 29, 227–231 (2003).
   Google Scholar
• Mikaeloff Y, Adamsbaun C, Husson B et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 127, 1942–1947 (2004).
   PubMed Web of Science ®Google Scholar
• Hahn CD, Shroff MM, Blaser SI, Banwell BL. MRI criteria for multiple sclerosis. Neurology 62, 806–808 (2004).
   PubMed Web of Science ®Google Scholar
• Fazekas F, Offenbacher H, Fuchs S et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38, 1822–1825 (1988).
   PubMed Web of Science ®Google Scholar
• Paty DW, Oger JJ, Kastrukoff LF et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and computed tomography (CT). Neurology 38, 180–185 (1988).
   PubMed Web of Science ®Google Scholar
• Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120, 2059–2069 (1997).
   PubMed Web of Science ®Google Scholar
• Mezzapesa D, Rocca MA, Falini A et al. A preliminary diffusion tensor and magnetization transfer magnetic resonance imaging study of early-onset multiple sclerosis. Arch. Neurol. 61, 366–368 (2004).
   PubMedGoogle Scholar
• Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology 63, 1966–1967 (2004).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis. Neurology 58(N2), 169–178 (2002).
   PubMedGoogle Scholar
• Barnes D, Hughes RA, Morris RW et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349, 902–906 (1997).
   PubMedGoogle Scholar
• Morrow SA, Stoian CA, Dmitrovic J et al. The bioavailability of intravenous methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63, 1079–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology, 49, 1404–1413 (1997).
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Rudick RA, De Masi R et al. Effects of IV methylprednisolone on brain atrophy in relapsing remitting MS. Neurology 57, 1239–1247 (2001).
   PubMed Web of Science ®Google Scholar
• Adams AB, Tyor WR, Holden KR. Interferon-β1b and childhood multiple sclerosis. Pediatr. Neurol. 21, 481–483 (1999).
   PubMed Web of Science ®Google Scholar
• Tenenbaun S, Martin S, Fejeman N. Disease-modifying therapies in childhood juvenile multiple sclerosis. Mult. Scler.7(Suppl.1), S57 (2001).
   Google Scholar
• Tenenbaun SN, Segura MJ. Clinical effects of disease-modifying therapies in early-onset multiple sclerosis. Neurology P06, 080 (2004).
   Google Scholar
• Mikaeloff Y, Moreau T, Debouverie M et al. Interferon-β treatment in patients with child-onset multiple sclerosis. J. Pediatr. 139, 443–446 (2001).
   PubMed Web of Science ®Google Scholar
• Moiola L. Efficacy and tolerability of immunomodulatory treatments in children with multiple sclerosis. Mult. Scler. P158 (2003).
   Google Scholar
• Kornek B, Bernert G, Balassy C et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 34, 120–126 (2003).
   PubMed Web of Science ®Google Scholar
• Pohl D, Rostasy K, Hanefeld F. The use of interferon-β1a (Rebif®) in children and adolescents with multiple sclerosis. Mult. Scler. P610 (2004).
   Google Scholar
• Ghezzi A, Gallo P, Marrosu MG et al. Effectiveness and tolerability of immunomodulatory drugs in multiple sclerosis during childhood or adolescence. Neurology 62, P06–P078 (2004).
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Amato MP, Gallo P et al. Disease modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (immunomodulatory treatment of early-onset MS) study group. Mult. Scler. P554 (2004).
   Google Scholar
• Ghezzi A, Ruggieri M, Trojano M, Filippi M and the ITEMS study. Italian studies on early-onset multiple sclerosis: the present and the future. Neurol. Sci. 25, S346–S349 (1997).
   Google Scholar
• Takahashi I, Sawaishi Y, Takeda O et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr. Neurol. 17, 83–87 (1997).
   PubMed Web of Science ®Google Scholar